Skip to content

Prevena to Prevent Surgical Site Infection After Emergency Abdominal Laparotomy

Standard Wound Dressing Versus Prophylactic Negative-pressure Wound Therapy After Emergency Laparotomy: a Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04496180
Acronym
CiPNT/SSI
Enrollment
334
Registered
2020-08-03
Start date
2021-09-01
Completion date
2025-09-01
Last updated
2021-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematoma, Length of Stay, Seroma, Surgical Site Infection

Keywords

pNPWT, PREVENA, SSI, morbidity, dehiscence

Brief summary

Post-operative wound complications in abdominal surgery have a major impact on patient outcomes and the real impact of Closed incision negative pressure therapy (CINVt) is not clear in the literature moreover concerning its potential economic benefits The hypothesis of this study is that CINPt has the potential to reduce Surgical Site Infections. Secondly the investigators aim to study the economic impact of CINPt used after abdominal emergency laparotomies.

Detailed description

Emergency laparotomies lead to increased morbidity and mortality rates. In this scenario the most frequent wound occurrences are represented by wound infections, skin dehiscence or parietal hernias. Despite standard surgical aseptically technique and perioperative prevention management of infections (e.g. antibiotics), wound complications after emergency laparotomies are still an important unmet challenge. Moreover, all these complications increase the cost of care requiring new managements. CINPt has been longly used to favour the successful healing of a plethora of open wounds. In particular CINPt is based on the application of local negative pressure to the wound surface. In case of open abdomens, the procedure is performed by applying a sterile abdominal dressing, which consists of a fenestrated soft plastic non-adherent layer with enclosed central foam, which is placed on the surface of the viscera. Then, two layers of porous sponge dressings are applied over the plastic layer. Finally, a transparent adhesive is placed over the foam and the wound to seal the abdominal cavity. The entire system is then connected, by suction tubes, to a device which ubiquitously applies negative pressure (cyclically or continuously) on the surface. The fluid from the wound is collected into a container. The benefits of negative pressure wound therapy have been reported to include removal of infectious material, reduction in oedema and improved perfusion to tissue. Since few years, a new negative pressure wound therapy has been created for closed wounds to reduce time of healing and avoid wound complications.

Interventions

DEVICEClosed incision negative pressure therapy versus standard dressing after emergency abdominal laparotomies

Target population is every patient undergoing a laparotomic procedure and responding to inclusion criteria marked in paragraph 3.8 (see forward) A member of the medical surgery team should apply the PREVENA just after the surgical procedure. A medical member (nurse specialist in wound care) of the surgical team removes the dressing. All other manipulations of the therapy unit, the connector and the cartridge can be carried out by any nurse practitioner in hospital or extra hospital environment but must warn the investigators. The aspiration will be stopped 24 hours before and the dressing is removed by a nurse at home or in the hospital. The specialized nurse who will take a photo and assess the condition of the wound in the treatment room. One of the investigators, non-operators, who will also assess the condition of the wound by photo.

Sponsors

Meyer Jeremy. PhD. Co-investigator. University Hospital, Geneva.
CollaboratorUNKNOWN
Peloso Andrea. PhD. Co-investigator. University Hospital, Geneva.
CollaboratorUNKNOWN
Ris Frederic. P.D. Clinical Professor. University Hospital, Geneva.
CollaboratorUNKNOWN
Toso Christian. PhD. Head of visceral surgery. University Hospital, Geneva.
CollaboratorUNKNOWN
Buchs C. Nicolas. P.D. Director of the project. University Hospital, Geneva.
CollaboratorUNKNOWN
University Hospital, Geneva
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

* Study Type: Interventional (Clinical Trial) * Estimated Enrollment: 334 * Allocation: Randomized control trial * Intervention Model: Parallel Assignment * Intervention Model Description: 2 separate treatment arms * Primary Purpose: Prevention * Official Title: Standard wound dressing versus prophylactic negative-pressure wound therapy after emergency laparotomy * Estimated Study Start Date: 09.2020 * Estimated Primary Completion Date:09.2021 * Estimated Study Completion Date: 09.2025

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patient * ≥10cm emergency median laparotomy * Abdominal wall and skin closure in first intent * Septic peritoneal cavity (purulent and/or fecaloid free liquid and/or abscess) * Informed written consent

Exclusion criteria

* No abdominal wound closure in first intent * Allergy or hypersensitivity to silver * Application of a mesh for abdominal wall closure * Patients under corticosteroids or other immunosuppressive treatment. * Women who are pregnant or breast-feeding. * Intention to become pregnant during the course of the study. * Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant. * Previous enrolment in the current study.

Design outcomes

Primary

MeasureTime frameDescription
To determine if the use of prophylactic negative-pressure wound therapy (Prevena) reduces the incidence of superficial surgical site infection after emergency laparotomy in patients at high-risk for SSIup to 30 days post procedureAny SSI may cause redness, delayed healing, fever, pain, tenderness, warmth, or swelling. Superficial site infection will be assessed by Wound Classification System Using the American College of Surgeons National Surgical Quality Improvement Program ACS-NSQIP : * Clean; these are uninfected operative wounds in which no inflammation. * Clean/contaminated; These are operative wounds in which the respiratory, alimentary, genital, or urinary tract is entered Under controlled conditions and without unusual contamination. * Contaminated; These include open, fresh, accidental wounds, operations with major breaks in sterile technique or gross spillage from the gastrointestinal tract, and incisions in which acute, non-purulent inflammation is encountered. * Dirty ; These include old traumatic wounds with retained devitalized tissue and those that involve existing clinical infection or perforated viscera.

Secondary

MeasureTime frameDescription
Length of stay (LOS) in days.30 days post procedureLOS is defined as days from operation to discharge; 30d LOS is defined as the index LOS plus all readmission days within 30d related to any wound complications.
30-day Return to Operating Room (ROR)30 days post procedureReoperation for wound complication within 30 days involving incision and drainage in the operating room; opening the skin to drain a superficial soft tissue infection at bedside or in the office is not considered reoperation.
Incidence rates of wound complications30 days post procedureIndividual rates of the incidence of each of the following: dehiscence (skin or fascia), seroma, lymph leak, infection, hematoma, ischemia and necrosis.

Other

MeasureTime frameDescription
A rate of parietal incisional hernia apparition after surgery2 years post procedureThis complication rate is multifactorial can be related to: * An wall abcess * Obesity with a BMI \> 35 Kg/m2 * medications * Malnutrition * Being an elderly adult * Smoking * Cancer * a weak immune system * diabetes

Contacts

Primary ContactZiad Abbassi, M.D.
Ziad.abbassi@hcuge.ch0041766931667
Backup ContactJérémy Meyer, Ph.D.
Jeremy.meyer@hcuge.ch0041763161984

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026